Results of multivariate modeling
. | No complete remission*† . | . | . | Progression under therapy* . | . | . | EFS event‡§ . | . | . | Death‡ . | . | . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | OR . | 95% Cl, upper limit; lower limit . | P∥ . | OR . | 95% Cl, upper limit; lower limit . | P∥ . | RR . | 95% Cl, upper limit; lower limit . | P∥ . | RR . | 95% Cl, upper limit; lower limit . | P∥ . | ||||||||
| CHOP-14 vs CHOP-21 | 0.45 | 0.28;0.73 | .001 | 0.34 | 0.19;0.61 | < .001 | 0.66 | 0.50;0.87 | .003 | 0.58 | 0.43;0.79 | < .001 | ||||||||
| CHOEP-21 vs CHOP-21 | 0.64 | 0.40;1.02 | .064 | 0.41 | 0.23;0.73 | .002 | 0.82 | 0.63;1.07 | .145 | 0.79 | 0.59;1.05 | .109 | ||||||||
| CHOEP-14 vs CHOP-21 | 0.57 | 0.36;0.92 | .020 | 0.24 | 0.13;0.46 | < .001 | 0.77 | 0.59;1.02 | .064 | 0.73 | 0.54;0.98 | .035 | ||||||||
| LDH greater than normal | 2.07 | 1.43;2.99 | < .001 | 2.23 | 1.37;3.63 | .001 | 1.75 | 1.40;2.17 | < .001 | 2.16 | 1.70;2.74 | < .001 | ||||||||
| Stage III/IV | 1.83 | 1.27;2.64 | .001 | 1.62 | 1.00;2.61 | .051 | 1.94 | 1.56;2.42 | < .001 | 1.72 | 1.36;2.18 | < .001 | ||||||||
| Bulky disease | 1.89 | 1.33;2.68 | < .001 | 2.07 | 1.32;3.24 | .002 | 1.10 | 0.90;1.36 | .353 | 1.15 | 0.92;1.44 | .227 | ||||||||
. | No complete remission*† . | . | . | Progression under therapy* . | . | . | EFS event‡§ . | . | . | Death‡ . | . | . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | OR . | 95% Cl, upper limit; lower limit . | P∥ . | OR . | 95% Cl, upper limit; lower limit . | P∥ . | RR . | 95% Cl, upper limit; lower limit . | P∥ . | RR . | 95% Cl, upper limit; lower limit . | P∥ . | ||||||||
| CHOP-14 vs CHOP-21 | 0.45 | 0.28;0.73 | .001 | 0.34 | 0.19;0.61 | < .001 | 0.66 | 0.50;0.87 | .003 | 0.58 | 0.43;0.79 | < .001 | ||||||||
| CHOEP-21 vs CHOP-21 | 0.64 | 0.40;1.02 | .064 | 0.41 | 0.23;0.73 | .002 | 0.82 | 0.63;1.07 | .145 | 0.79 | 0.59;1.05 | .109 | ||||||||
| CHOEP-14 vs CHOP-21 | 0.57 | 0.36;0.92 | .020 | 0.24 | 0.13;0.46 | < .001 | 0.77 | 0.59;1.02 | .064 | 0.73 | 0.54;0.98 | .035 | ||||||||
| LDH greater than normal | 2.07 | 1.43;2.99 | < .001 | 2.23 | 1.37;3.63 | .001 | 1.75 | 1.40;2.17 | < .001 | 2.16 | 1.70;2.74 | < .001 | ||||||||
| Stage III/IV | 1.83 | 1.27;2.64 | .001 | 1.62 | 1.00;2.61 | .051 | 1.94 | 1.56;2.42 | < .001 | 1.72 | 1.36;2.18 | < .001 | ||||||||
| Bulky disease | 1.89 | 1.33;2.68 | < .001 | 2.07 | 1.32;3.24 | .002 | 1.10 | 0.90;1.36 | .353 | 1.15 | 0.92;1.44 | .227 | ||||||||
OR indicates odds ratio; and RR, relative risk.
Logistic regression.
No complete remission: partial response, stable disease, progression under therapy, therapy-associated deaths, unknown response, additional therapy.
Cox proportional models.
EFS events: progression, no complete remission at the end of treatment, relapse after complete remission, death, unplanned additional treatment or change of treatment, what ever comes first.
Due to multiple comparisons in this analysis, only P values less than .016 (0.05:3) should be considered significant.